Pathologic Complete Response (pCR) Rate and Predictors of Response to Taxane, Trastuzumab, and Pertuzumab in HER2-Positive Breast Cancer: Secondary Analyses of EA1181/CompassHER2 pCR
用户jVLEDgPjrAis
2小时前
13
10
已完结
1. 当前求助状态已完结, 请及时下载应助文件
2. 系统将在 2026-08-28 16:34:13 删除文件
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规

